Supplementary Information Regarding the 2024 Annual Report This section provides supplementary details on the company's 2024 annual report, primarily focusing on share option scheme changes and participant eligibility Details of Share Option Scheme This chapter provides supplementary information on the company's share option scheme for the year ended December 31, 2024, detailing changes in options granted to directors and employees and defining eligible participants for new schemes Details of Share Option Changes for the Year Ended December 31, 2024 | Participant Category | Grant Date | Exercise Price (HKD) | Balance as of January 1, 2024 | Expired During Year | Cancelled During Year | Balance as of December 31, 2024 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Directors | June 1, 2020 | 0.188 | 11,200,000 | (2,400,000) | (8,800,000) | — | | Employees | June 1, 2020 | 0.188 | 57,000,000 | — | (57,000,000) | — | - The new share option scheme's eligible participants include directors and employees of the Group and its associated entities, as well as contractors, suppliers, and consultants beneficial to the Group's long-term development4 Change in Use of Proceeds This section outlines the company's plan to reallocate unused proceeds to support the development of its Traditional Chinese Medicine business Proceeds Reallocation Plan and Rationale The company plans to reallocate approximately HKD 20 million of unutilized proceeds to support Traditional Chinese Medicine business development, primarily for supply chain and drug procurement, following the acquisition of Bozhou Lelaohao Pharmaceutical Co., Ltd. in July 2025, with all funds expected to be utilized by December 31, 2026 Proceeds Use Change Plan | Proposed Use | Amount (HKD) | Estimated Completion Date of Utilization | | :--- | :--- | :--- | | Traditional Chinese Medicine Business Development | Approx. 20 Million | December 31, 2026 | | General Working Capital | Remaining Unutilized Net Proceeds | December 31, 2026 | - The primary reason for changing the use of proceeds is to support the business development of the newly acquired Bozhou Lelaohao Pharmaceutical Co., Ltd., which holds a drug operating license and engages in wholesale and retail distribution of pharmaceuticals7 - Reallocated funds will primarily be used for supply chain development and drug procurement to support the Group's Traditional Chinese Medicine business, leveraging the acquisition to explore upstream and downstream opportunities in the pharmaceutical value chain7
乐氏国际控股(01529) - 2025 - 年度业绩